These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 17100315)

  • 41. [Immunoglobulin preparations].
    Ono Y
    Nihon Rinsho; 2012 Apr; 70(4):629-34. PubMed ID: 22568145
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Virus reduction in an intravenous immunoglobulin by solvent/detergent treatment, ion-exchange chromatography and terminal low pH incubation.
    Roberts PL; Dunkerley C; Walker C
    Biologicals; 2012 Sep; 40(5):345-52. PubMed ID: 22658506
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapeutic intravenous immunoglobulins.
    Lemieux R; Bazin R; Néron S
    Mol Immunol; 2005 May; 42(7):839-48. PubMed ID: 15829272
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The disease-specific arm of the therapeutic effect of intravenous immunoglobulin in autoimmune diseases: experimental autoimmune myasthenia gravis as a model.
    Fuchs S; Feferman T; Meidler R; Brenner T; Laub O; Souroujon MC
    Isr Med Assoc J; 2008 Jan; 10(1):58-60. PubMed ID: 18300576
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunoglobulin replacement therapy in primary antibody deficiency diseases--maximizing success.
    Durandy A; Wahn V; Petteway S; Gelfand EW
    Int Arch Allergy Immunol; 2005 Mar; 136(3):217-29. PubMed ID: 15713984
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of target antigens of self-reactive IgG in intravenous immunoglobulin preparations.
    Bussone G; Dib H; Dimitrov JD; Camoin L; Broussard C; Tamas N; Guillevin L; Kaveri SV; Mouthon L
    Proteomics; 2009 Apr; 9(8):2253-62. PubMed ID: 19296548
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Increased blood plasma concentrations of TGF-beta1 and TGF-beta2 after treatment with intravenous immunoglobulins in childhood autoimmune diseases.
    Rissmann A; Pieper S; Adams I; Brune T; Wiemann D; Reinhold D
    Pediatr Allergy Immunol; 2009 May; 20(3):261-5. PubMed ID: 18761651
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Increased risk of adverse events when changing intravenous immunoglobulin preparations.
    Ameratunga R; Sinclair J; Kolbe J
    Clin Exp Immunol; 2004 Apr; 136(1):111-3. PubMed ID: 15030521
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Economical impact of plasma fractionation project in Iran on affordability of plasma-derived medicines.
    Cheraghali AM; Aboofazeli R
    Transfus Med; 2009 Dec; 19(6):363-8. PubMed ID: 19778319
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterization of immunoglobulin G fragments in liquid intravenous immunoglobulin products.
    Diemel RV; ter Hart HG; Derksen GJ; Koenderman AH; Aalberse RC
    Transfusion; 2005 Oct; 45(10):1601-9. PubMed ID: 16181211
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differences between IGIV products: impact on clinical outcome.
    Gelfand EW
    Int Immunopharmacol; 2006 Apr; 6(4):592-9. PubMed ID: 16504921
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The viral safety of intravenous immune globulin.
    Yap PL
    Clin Exp Immunol; 1996 May; 104 Suppl 1():35-42. PubMed ID: 8625542
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High dose intravenous immunoglobulin treatment: mechanisms of action.
    Boros P; Gondolesi G; Bromberg JS
    Liver Transpl; 2005 Dec; 11(12):1469-80. PubMed ID: 16315304
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Should therapeutic immunoglobulin be considered a generic product? An evidence-based approach.
    Misbah SA
    J Allergy Clin Immunol Pract; 2013; 1(6):567-72. PubMed ID: 24565702
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Intravenous immunoglobulin therapy].
    Mouthon L
    Rev Prat; 2005 May; 55(10):1049-56. PubMed ID: 16097244
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Single-use disposable technologies for biopharmaceutical manufacturing.
    Shukla AA; Gottschalk U
    Trends Biotechnol; 2013 Mar; 31(3):147-54. PubMed ID: 23178074
    [TBL] [Abstract][Full Text] [Related]  

  • 57. What is the contents of the magic draft IVIg?
    Seite JF; Shoenfeld Y; Youinou P; Hillion S
    Autoimmun Rev; 2008 Jun; 7(6):435-9. PubMed ID: 18558358
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Applications of process analytical technology to crystallization processes.
    Yu LX; Lionberger RA; Raw AS; D'Costa R; Wu H; Hussain AS
    Adv Drug Deliv Rev; 2004 Feb; 56(3):349-69. PubMed ID: 14962586
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A flow-through chromatography process for influenza A and B virus purification.
    Weigel T; Solomaier T; Peuker A; Pathapati T; Wolff MW; Reichl U
    J Virol Methods; 2014 Oct; 207():45-53. PubMed ID: 24992667
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunoglobulin replacement therapy: a twenty-year review and current update.
    Saeedian M; Randhawa I
    Int Arch Allergy Immunol; 2014; 164(2):151-66. PubMed ID: 25011425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.